1275034-58-6

Basic information

• Product Name: C₂₄H₂₅N₅O
• Synonyms: C₂₄H₂₅N₅O
• CAS NO: 1275034-58-6
• Molecular Weight: 399.495
• Mol File: 1275034-58-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₄H₂₅N₅O(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₄H₂₅N₅O(1275034-58-6)
• EPA Substance Registry System: C₂₄H₂₅N₅O(1275034-58-6)

Safety Data

• Hazardous Substances Data: 1275034-58-6(Hazardous Substances Data)

Upstream product

• 1275019-54-9 C₃₄H₄₁N₅O₅ 
• 1208008-44-9 (S)-2-(5-ethynyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1208008-43-8 C₂₁H₂₉N₃O₂Si 
• 1208007-67-3 1,1-dimethylethyl (2S)-2-(5-bromo-1H-benzimidazol-2-yl)-1-pyrrolidinecarboxylate 
• 1228553-72-7 (2S)-1-tert-butoxycarbonyl-2-(2-amino-4-bromophenylaminoacyl)pyrrolidine 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.